NCT03757559 - A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users | Biotech Hunter

Enrollment

226

Participants

Timeline

Start Date

April 15, 2013

Primary Completion Date

March 8, 2014

Study Completion Date

March 8, 2014

Conditions

Abuse, Drug

Interventions

DRUG

Cebranopadol 100 micrograms

Tablets were taken under fasted conditions with non-carbonated water.

DRUG

Cebranopadol 400 micrograms

Tablets were taken under fasted conditions with non-carbonated water.

DRUG

Hydromorphone hydrochloride 4 milligrams

Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.

DRUG

Placebo matching hydromorphone

Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.

DRUG

Placebo matching cebranopadol

Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.

Trial Locations (1)

INC Research, Toronto

All Listed Sponsors

lead

Tris Pharma, Inc.

INDUSTRY